Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Cited by (388)

Items 101–200 of 388

1. Tim‐3 and its role in regulating anti‐tumor immunity
   Das, Madhumita, Zhu, Chen, Kuchroo, Vijay K. · 2017 · Immunological Reviews
2. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
   Hsu, Joy, Hodgins, Jonathan J., Marathe, Malvika, Nicolai, Chris J., Bourgeois-Daigneault, Marie-Claude, Trevino, Troy N., Azimi, Camillia S., Scheer, Amit K., Randolph, Haley E., Thompson, Thornton W. et al. · 2018 · Journal of Clinical Investigation
3. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
   Amaria, Rodabe N., Reddy, Sangeetha M., Tawbi, Hussein A., Davies, Michael A., Ross, Merrick I., Glitza, Isabella C., Cormier, Janice N., Lewis, Carol, Hwu, Wen-Jen, Hanna, Ehab et al. · 2018 · Nature Medicine
4. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
   Rafiq, Sarwish, Yeku, Oladapo O, Jackson, Hollie J, Purdon, Terence J, van Leeuwen, Dayenne G, Drakes, Dylan J, Song, Mei, Miele, Matthew M, Li, Zhuoning, Wang, Pei et al. · 2018 · Nature Biotechnology
5. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
   Allen, Elizabeth, Jabouille, Arnaud, Rivera, Lee B., Lodewijckx, Inge, Missiaen, Rindert, Steri, Veronica, Feyen, Kevin, Tawney, Jaime, Hanahan, Douglas, Michael, Iacovos P. et al. · 2017 · Science Translational Medicine
6. Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
   van Rooij, Nienke, van Buuren, Marit M., Philips, Daisy, Velds, Arno, Toebes, Mireille, Heemskerk, Bianca, van Dijk, Laura J.A., Behjati, Sam, Hilkmann, Henk, el Atmioui, Dris et al. · 2013 · Journal of Clinical Oncology
7. The Next Decade of Immune Checkpoint Therapy
   Sharma, Padmanee, Siddiqui, Bilal A., Anandhan, Swetha, Yadav, Shalini S., Subudhi, Sumit K., Gao, Jianjun, Goswami, Sangeeta, Allison, James P. · 2021 · Cancer Discovery
8. Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
   Highfill, Steven L., Cui, Yongzhi, Giles, Amber J., Smith, Jillian P., Zhang, Hua, Morse, Elizabeth, Kaplan, Rosandra N., Mackall, Crystal L. · 2014 · Science Translational Medicine
9. Immunity, inflammation and cancer: a leading role for adenosine
   Antonioli, Luca, Blandizzi, Corrado, Pacher, Pál, Haskó, György · 2013 · Nature Reviews Cancer
10. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
    Rupp, Levi J., Schumann, Kathrin, Roybal, Kole T., Gate, Rachel E., Ye, Chun J., Lim, Wendell A., Marson, Alexander · 2017 · Scientific Reports
11. Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
    Schietinger, Andrea, Philip, Mary, Krisnawan, Varintra E., Chiu, Edison Y., Delrow, Jeffrey J., Basom, Ryan S., Lauer, Peter, Brockstedt, Dirk G., Knoblaugh, Sue E., Hämmerling, Günter J. et al. · 2016 · Immunity
12. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
    Crespo, Joel, Sun, Haoyu, Welling, Theodore H, Tian, Zhigang, Zou, Weiping · 2013 · Current Opinion in Immunology
13. Immunogenicity of somatic mutations in human gastrointestinal cancers
    Tran, Eric, Ahmadzadeh, Mojgan, Lu, Yong-Chen, Gros, Alena, Turcotte, Simon, Robbins, Paul F., Gartner, Jared J., Zheng, Zhili, Li, Yong F., Ray, Satyajit et al. · 2015 · Science
14. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
    Abiko, K, Matsumura, N, Hamanishi, J, Horikawa, N, Murakami, R, Yamaguchi, K, Yoshioka, Y, Baba, T, Konishi, I, Mandai, M · 2015 · British Journal of Cancer
15. WNT/β-catenin pathway activation correlates with immune exclusion across human cancers
    Luke, Jason J., Bao, Riyue, Sweis, Randy F., Spranger, Stefani, Gajewski, Thomas F. · 2019 · Clinical Cancer Research
16. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
    Krieg, Carsten, Nowicka, Malgorzata, Guglietta, Silvia, Schindler, Sabrina, Hartmann, Felix J, Weber, Lukas M, Dummer, Reinhard, Robinson, Mark D, Levesque, Mitchell P, Becher, Burkhard · 2018 · Nature Medicine
17. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment
    Bender, Mackenzie J., McPherson, Alex C., Phelps, Catherine M., Pandey, Surya P., Laughlin, Colin R., Shapira, Jake H., Medina Sanchez, Luzmariel, Rana, Mohit, Richie, Tanner G., Mims, Tahliyah S. et al. · 2023 · Cell
18. Human FOXP3+ Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer
    Wing, James B., Tanaka, Atsushi, Sakaguchi, Shimon · 2019 · Immunity
19. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy
    Zamarin, Dmitriy, Holmgaard, Rikke B., Subudhi, Sumit K., Park, Joon Seok, Mansour, Mena, Palese, Peter, Merghoub, Taha, Wolchok, Jedd D., Allison, James P. · 2014 · Science Translational Medicine
20. Turning the corner on therapeutic cancer vaccines
    Hollingsworth, Robert E., Jansen, Kathrin · 2019 · npj Vaccines
21. PDL1 Regulation by p53 via miR-34
    Cortez, Maria Angelica, Ivan, Cristina, Valdecanas, David, Wang, Xiaohong, Peltier, Heidi J., Ye, Yuping, Araujo, Luiz, Carbone, David P., Shilo, Konstantin, Giri, Dipak K et al. · 2016 · JNCI: Journal of the National Cancer Institute
22. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
    Mezzadra, Riccardo, Sun, Chong, Jae, Lucas T., Gomez-Eerland, Raquel, de Vries, Evert, Wu, Wei, Logtenberg, Meike E. W., Slagter, Maarten, Rozeman, Elisa A., Hofland, Ingrid et al. · 2017 · Nature
23. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
    Yang, H, Bueso-Ramos, C, DiNardo, C, Estecio, M R, Davanlou, M, Geng, Q-R, Fang, Z, Nguyen, M, Pierce, S, Wei, Y et al. · 2014 · Leukemia
24. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
    Coelho, Matthew A., de Carné Trécesson, Sophie, Rana, Sareena, Zecchin, Davide, Moore, Christopher, Molina-Arcas, Miriam, East, Philip, Spencer-Dene, Bradley, Nye, Emma, Barnouin, Karin et al. · 2017 · Immunity
25. Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
    Byun, David J., Wolchok, Jedd D., Rosenberg, Lynne M., Girotra, Monica · 2017 · Nature Reviews Endocrinology
26. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy
    Arlauckas, Sean P., Garris, Christopher S., Kohler, Rainer H., Kitaoka, Maya, Cuccarese, Michael F., Yang, Katherine S., Miller, Miles A., Carlson, Jonathan C., Freeman, Gordon J., Anthony, Robert M. et al. · 2017 · Science Translational Medicine
27. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
    Kim, KiBem, Skora, Andrew D., Li, Zhaobo, Liu, Qiang, Tam, Ada J., Blosser, Richard L., Diaz, Luis A., Papadopoulos, Nickolas, Kinzler, Kenneth W., Vogelstein, Bert et al. · 2014 · Proceedings of the National Academy of Sciences
28. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
    Zhu, Andrew X., Abbas, Alexander R., de Galarreta, Marina Ruiz, Guan, Yinghui, Lu, Shan, Koeppen, Hartmut, Zhang, Wenjun, Hsu, Chih-Hung, He, Aiwu Ruth, Ryoo, Baek-Yeol et al. · 2022 · Nature Medicine
29. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma
    Daud, Adil I., Wolchok, Jedd D., Robert, Caroline, Hwu, Wen-Jen, Weber, Jeffrey S., Ribas, Antoni, Hodi, F. Stephen, Joshua, Anthony M., Kefford, Richard, Hersey, Peter et al. · 2016 · Journal of Clinical Oncology
30. The immunological anatomy of the skin
    Kabashima, Kenji, Honda, Tetsuya, Ginhoux, Florent, Egawa, Gyohei · 2019 · Nature Reviews Immunology
31. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
    Gurbatri, Candice R., Lia, Ioana, Vincent, Rosa, Coker, Courtney, Castro, Samuel, Treuting, Piper M., Hinchliffe, Taylor E., Arpaia, Nicholas, Danino, Tal · 2020 · Science Translational Medicine
32. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
    Müller, Judith, Krijgsman, Oscar, Tsoi, Jennifer, Robert, Lidia, Hugo, Willy, Song, Chunying, Kong, Xiangju, Possik, Patricia A., Cornelissen-Steijger, Paulien D. M., Foppen, Marnix H Geukes et al. · 2014 · Nature Communications
33. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer
    Liao, Wenting, Overman, Michael J., Boutin, Adam T., Shang, Xiaoying, Zhao, Di, Dey, Prasenjit, Li, Jiexi, Wang, Guocan, Lan, Zhengdao, Li, Jun et al. · 2019 · Cancer Cell
34. Drug resistance and new therapies in colorectal cancer
    Jeught, Kevin Van der, Xu, Han-Chen, Li, Yu-Jing, Lu, Xiong-Bin, Ji, Guang · 2018 · World Journal of Gastroenterology
35. Tumor-Associated Macrophages: Recent Insights and Therapies
    Zhou, Jiawei, Tang, Ziwei, Gao, Siyang, Li, Chunyu, Feng, Yiting, Zhou, Xikun · 2020 · Frontiers in Oncology
36. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
    Yearley, Jennifer H., Gibson, Christopher, Yu, Ni, Moon, Christina, Murphy, Erin, Juco, Jonathan, Lunceford, Jared, Cheng, Jonathan, Chow, Laura Q.M., Seiwert, Tanguy Y. et al. · 2017 · Clinical Cancer Research
37. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
    Bardhan, Kankana, Anagnostou, Theodora, Boussiotis, Vassiliki A. · 2016 · Frontiers in Immunology
38. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
    Picarda, Elodie, Ohaegbulam, Kim C., Zang, Xingxing · 2016 · Clinical Cancer Research
39. The hallmarks of successful anticancer immunotherapy
    Galluzzi, Lorenzo, Chan, Timothy A., Kroemer, Guido, Wolchok, Jedd D., López-Soto, Alejandro · 2018 · Science Translational Medicine
40. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
    Gao, Jianjun, Ward, John F, Pettaway, Curtis A, Shi, Lewis Z, Subudhi, Sumit K, Vence, Luis M, Zhao, Hao, Chen, Jianfeng, Chen, Hong, Efstathiou, Eleni et al. · 2017 · Nature Medicine
41. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
    Grosser, Rachel, Cherkassky, Leonid, Chintala, Navin, Adusumilli, Prasad S. · 2019 · Cancer Cell
42. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC
    Jin, Yueping, Dong, Hui, Xia, Liliang, Yang, Yi, Zhu, Yongqiang, Shen, Yan, Zheng, Huajun, Yao, Chengcheng, Wang, Ying, Lu, Shun · 2019 · Journal of Thoracic Oncology
43. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
    Weide, Benjamin, Martens, Alexander, Hassel, Jessica C., Berking, Carola, Postow, Michael A., Bisschop, Kees, Simeone, Ester, Mangana, Johanna, Schilling, Bastian, Di Giacomo, Anna Maria et al. · 2016 · Clinical Cancer Research
44. PD‐L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
    Peng, Qi, Qiu, Xiangyan, Zhang, Zihan, Zhang, Silin, Zhang, Yuanyuan, Liang, Yong, Guo, Jingya, Peng, Hua, Chen, Mingyi, Fu, Yang-Xin et al. · 2020 · Nature Communications
45. Atezolizumab with or without Cobimetinib versus Regorafenib in Previously Treated Metastatic Colorectal Cancer (IMblaze370): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial
    Eng, Cathy, Kim, Tae Won, Bendell, Johanna, Argilés, Guillem, Tebbutt, Niall C, Di Bartolomeo, Maria, Falcone, Alfredo, Fakih, Marwan, Kozloff, Mark, Segal, Neil H et al. · 2019 · The Lancet Oncology
46. Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells
    Lakins, Matthew A., Ghorani, Ehsan, Munir, Hafsa, Martins, Carla P., Shields, Jacqueline D. · 2018 · Nature Communications
47. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature
    Cuzzubbo, S., Javeri, F., Tissier, M., Roumi, A., Barlog, C., Doridam, J., Lebbe, C., Belin, C., Ursu, R., Carpentier, A.F. · 2017 · European Journal of Cancer
48. Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
    Thompson, John A., Schneider, Bryan J., Brahmer, Julie, Andrews, Stephanie, Armand, Philippe, Bhatia, Shailender, Budde, Lihua E., Costa, Luciano, Davies, Marianne, Dunnington, David et al. · 2019 · Journal of the National Comprehensive Cancer Network
49. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment
    Spranger, Stefani, Koblish, Holly K, Horton, Brendan, Scherle, Peggy A, Newton, Robert, Gajewski, Thomas F · 2014 · Journal for ImmunoTherapy of Cancer
50. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
    Martens, Alexander, Wistuba-Hamprecht, Kilian, Foppen, Marnix Geukes, Yuan, Jianda, Postow, Michael A., Wong, Phillip, Romano, Emanuela, Khammari, Amir, Dreno, Brigitte, Capone, Mariaelena et al. · 2016 · Clinical Cancer Research
51. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
    Weber, Jeffrey S., Kudchadkar, Ragini Reiney, Yu, Bin, Gallenstein, Donna, Horak, Christine E., Inzunza, H. David, Zhao, Xiuhua, Martinez, Alberto J., Wang, Wenshi, Gibney, Geoffrey et al. · 2013 · Journal of Clinical Oncology
52. Tumor-repopulating cells induce PD-1 expression in CD8(+) T cells by transferring kynurenine and AhR activation
    Liu, Yuying, Liang, Xiaoyu, Dong, Wenqian, Fang, Yi, Lv, Jiadi, Zhang, Tianzhen, Fiskesund, Roland, Xie, Jing, Liu, Jinyan, Yin, Xiaonan et al. · 2018 · Cancer Cell
53. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
    Loi, Sherene, Dushyanthen, Sathana, Beavis, Paul A., Salgado, Roberto, Denkert, Carsten, Savas, Peter, Combs, Susan, Rimm, David L., Giltnane, Jennifer M., Estrada, Monica V. et al. · 2016 · Clinical Cancer Research
54. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
    Peng, Jin, Hamanishi, Junzo, Matsumura, Noriomi, Abiko, Kaoru, Murat, Kumuruz, Baba, Tsukasa, Yamaguchi, Ken, Horikawa, Naoki, Hosoe, Yuko, Murphy, Susan K. et al. · 2015 · Cancer Research
55. Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements
    Nishino, Mizuki, Giobbie-Hurder, Anita, Gargano, Maria, Suda, Margaret, Ramaiya, Nikhil H., Hodi, F. Stephen · 2013 · Clinical Cancer Research
56. Genetically engineered mouse models in oncology research and cancer medicine
    Kersten, Kelly, de Visser, Karin E, van Miltenburg, Martine H, Jonkers, Jos · 2017 · EMBO Molecular Medicine
57. Regulated cell death and inflammation: an auto-amplification loop causes organ failure
    Linkermann, Andreas, Stockwell, Brent R., Krautwald, Stefan, Anders, Hans-Joachim · 2014 · Nature Reviews Immunology
58. Comprehensive analysis of the clinical immuno-oncology landscape
    Tang, J., Shalabi, A., Hubbard-Lucey, V.M. · 2018 · Annals of Oncology
59. TGFβ is a master regulator of radiation therapy-induced antitumor immunity
    Vanpouille-Box, Claire, Diamond, Julie M., Pilones, Karsten A., Zavadil, Jiri, Babb, James S., Formenti, Silvia C., Barcellos-Hoff, Mary Helen, Demaria, Sandra · 2015 · Cancer Research
60. VISTA is an immune checkpoint molecule for human T cells
    Lines, J. Louise, Pantazi, Eirini, Mak, Justin, Sempere, Lorenzo F., Wang, Li, O'Connell, Samuel, Ceeraz, Sabrina, Suriawinata, Arief A., Yan, Shaofeng, Ernstoff, Marc S. et al. · 2014 · Cancer Research
61. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints
    Mikucki, M. E., Fisher, D. T., Matsuzaki, J., Skitzki, J. J., Gaulin, N. B., Muhitch, J. B., Ku, A. W., Frelinger, J. G., Odunsi, K., Gajewski, T. F. et al. · 2015 · Nature Communications
62. The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes
    Huang, Qizhao, Wu, Xia, Wang, Zhiming, Chen, Xiangyu, Wang, Lisha, Lu, Yijun, Xiong, Dan, Liu, Qiao, Tian, Yuhan, Lin, Huayu et al. · 2022 · Cell
63. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
    Johnson, Douglas B., Frampton, Garrett M., Rioth, Matthew J., Yusko, Erik, Xu, Yaomin, Guo, Xingyi, Ennis, Riley C., Fabrizio, David, Chalmers, Zachary R., Greenbowe, Joel et al. · 2016 · Cancer Immunology Research
64. Drug development in the era of precision medicine
    Dugger, Sarah A., Platt, Adam, Goldstein, David B. · 2018 · Nature Reviews Drug Discovery
65. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
    Xu, Jianming, Zhang, Yun, Jia, Ru, Yue, Chunyan, Chang, Lianpeng, Liu, Rongrui, Zhang, Gairong, Zhao, Chuanhua, Zhang, Yaoyue, Chen, Chunxia et al. · 2019 · Clinical Cancer Research
66. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
    Liu, Xinjian, Bao, Xuhui, Hu, Mengjie, Chang, Hanman, Jiao, Meng, Cheng, Jin, Xie, Liyi, Huang, Qian, Li, Fang, Li, Chuan-Yuan · 2020 · Nature
67. Reversing T-cell Dysfunction and Exhaustion in Cancer
    Zarour, Hassane M. · 2016 · Clinical Cancer Research
68. Analyses of repeated failures in cancer therapy for solid tumors: Poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs
    Maeda, Hiroshi, Khatami, Mahin · 2018 · Clinical and Translational Medicine
69. The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
    Jiang, Xiaofeng, Zhou, Jun, Giobbie-Hurder, Anita, Wargo, Jennifer, Hodi, F. Stephen · 2013 · Clinical Cancer Research
70. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma
    Winograd, Rafael, Byrne, Katelyn T., Evans, Rebecca A., Odorizzi, Pamela M., Meyer, Anders R.L., Bajor, David L., Clendenin, Cynthia, Stanger, Ben Z., Furth, Emma E., Wherry, E. John et al. · 2015 · Cancer Immunology Research
71. Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging
    Thomas, Rachel, Wang, Weikan, Su, Dong-Ming · 2020 · Immunity & Ageing
72. Exploiting the curative potential of adoptive T‐cell therapy for cancer
    Hinrichs, Christian S., Rosenberg, Steven A. · 2014 · Immunological Reviews
73. CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in mice
    Chen, Yunching, Ramjiawan, Rakesh R., Reiberger, Thomas, Ng, Mei R., Hato, Tai, Huang, Yuhui, Ochiai, Hiroki, Kitahara, Shuji, Unan, Elizabeth C., Reddy, Tejaswini P. et al. · 2015 · Hepatology
74. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
    Ohashi, Kadoaki, Maruvka, Yosef E., Michor, Franziska, Pao, William · 2013 · Journal of Clinical Oncology
75. Genomic correlates of response to immune checkpoint blockade
    Keenan, Tanya E., Burke, Kelly P., Van Allen, Eliezer M. · 2019 · Nature Medicine
76. PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
    Salmaninejad, Arash, Valilou, Saeed Farajzadeh, Shabgah, Arezoo Gowhari, Aslani, Saeed, Alimardani, Malihe, Pasdar, Alireza, Sahebkar, Amirhossein · 2019 · Journal of Cellular Physiology
77. Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
    Sanlorenzo, Martina, Vujic, Igor, Daud, Adil, Algazi, Alain, Gubens, Matthew, Luna, Sara Alcántara, Lin, Kevin, Quaglino, Pietro, Rappersberger, Klemens, Ortiz-Urda, Susana · 2015 · JAMA Dermatology
78. 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
    Tran, Eric, Robbins, Paul F, Rosenberg, Steven A · 2017 · Nature Immunology
79. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology
    Nuhn, Philipp, De Bono, Johann S., Fizazi, Karim, Freedland, Stephen J., Grilli, Maurizio, Kantoff, Philip W., Sonpavde, Guru, Sternberg, Cora N., Yegnasubramanian, Srinivasan, Antonarakis, Emmanuel S. · 2019 · European Urology
80. Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells
    Purwar, Rahul, Schlapbach, Christoph, Xiao, Sheng, Kang, Hong Soon, Elyaman, Wassim, Jiang, Xiaodong, Jetten, Anton M, Khoury, Samia J, Fuhlbrigge, Robert C, Kuchroo, Vijay K et al. · 2012 · Nature Medicine
81. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade
    Woods, David M., Sodré, Andressa L., Villagra, Alejandro, Sarnaik, Amod, Sotomayor, Eduardo M., Weber, Jeffrey · 2015 · Cancer Immunology Research
82. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
    Ryder, Mabel, Callahan, Margaret, Postow, Michael A, Wolchok, Jedd, Fagin, James A · 2014 · Endocrine-Related Cancer
83. Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma
    Prat, Aleix, Navarro, Alejandro, Paré, Laia, Reguart, Noemí, Galván, Patricia, Pascual, Tomás, Martínez, Alex, Nuciforo, Paolo, Comerma, Laura, Alos, Llucia et al. · 2017 · Cancer Research
84. The emerging role of epigenetic therapeutics in immuno-oncology
    Topper, Michael J., Vaz, Michelle, Marrone, Kristen A., Brahmer, Julie R., Baylin, Stephen B. · 2020 · Nature Reviews Clinical Oncology
85. Endocrine toxicities of immune checkpoint inhibitors
    Wright, Jordan J., Powers, Alvin C., Johnson, Douglas B. · 2021 · Nature Reviews Endocrinology
86. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines
    Peng, Weiyi, Liu, Chengwen, Xu, Chunyu, Lou, Yanyan, Chen, Jieqing, Yang, Yan, Yagita, Hideo, Overwijk, Willem W., Lizée, Gregory, Radvanyi, Laszlo et al. · 2012 · Cancer Research
87. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody
    Segal, Neil H., Logan, Theodore F., Hodi, F. Stephen, McDermott, David, Melero, Ignacio, Hamid, Omid, Schmidt, Henrik, Robert, Caroline, Chiarion-Sileni, Vanna, Ascierto, Paolo A. et al. · 2017 · Clinical Cancer Research
88. New perspectives for targeting RAF kinase in human cancer
    Karoulia, Zoi, Gavathiotis, Evripidis, Poulikakos, Poulikos I. · 2017 · Nature Reviews Cancer
89. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor
    Belum, V.R., Benhuri, B., Postow, M.A., Hellmann, M.D., Lesokhin, A.M., Segal, N.H., Motzer, R.J., Wu, S., Busam, K.J., Wolchok, J.D. et al. · 2016 · European Journal of Cancer
90. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor
    Ruffo, Elisa, Wu, Richard C., Bruno, Tullia C., Workman, Creg J., Vignali, Dario A.A. · 2019 · Seminars in Immunology
91. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways
    Zhao, Yunlong, Lee, Calvin K., Lin, Chia-Hao, Gassen, Rodrigo B., Xu, Xiaozheng, Huang, Zhe, Xiao, Changchun, Bonorino, Cristina, Lu, Li-Fan, Bui, Jack D. et al. · 2019 · Immunity
92. Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
    Corsello, Salvatore Maria, Barnabei, Agnese, Marchetti, Paolo, De Vecchis, Liana, Salvatori, Roberto, Torino, Francesco · 2013 · The Journal of Clinical Endocrinology & Metabolism
93. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial
    Sharma, Padmanee, Pachynski, Russell K., Narayan, Vivek, Fléchon, Aude, Gravis, Gwenaelle, Galsky, Matthew D., Mahammedi, Hakim, Patnaik, Akash, Subudhi, Sumit K., Ciprotti, Marika et al. · 2020 · Cancer Cell
94. Innate immune signaling and regulation in cancer immunotherapy
    Corrales, Leticia, Matson, Vyara, Flood, Blake, Spranger, Stefani, Gajewski, Thomas F · 2017 · Cell Research
95. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
    Usmani, Saad Z., Weiss, Brendan M., Plesner, Torben, Bahlis, Nizar J., Belch, Andrew, Lonial, Sagar, Lokhorst, Henk M., Voorhees, Peter M., Richardson, Paul G., Chari, Ajai et al. · 2016 · Blood
96. Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer
    Vanguri, Rami S., Luo, Jia, Aukerman, Andrew T., Egger, Jacklynn V., Fong, Christopher J., Horvat, Natally, Pagano, Andrew, Araujo-Filho, Jose de Arimateia Batista, Geneslaw, Luke, Rizvi, Hira et al. · 2022 · Nature Cancer
97. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
    Mayoux, Maud, Roller, Andreas, Pulko, Vesna, Sammicheli, Stefano, Chen, Stanford, Sum, Eva, Jost, Christian, Fransen, Marieke F., Buser, Regula B., Kowanetz, Marcin et al. · 2020 · Science Translational Medicine
98. Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma
    Orillion, Ashley, Hashimoto, Ayumi, Damayanti, Nur, Shen, Li, Adelaiye-Ogala, Remi, Arisa, Sreevani, Chintala, Sreenivasulu, Ordentlich, Peter, Kao, Chingai, Elzey, Bennett et al. · 2017 · Clinical Cancer Research
99. The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer
    Peng, Zhi, Cheng, Siyuan, Kou, Yan, Wang, Ziqi, Jin, Rong, Hu, Han, Zhang, Xiaotian, Gong, Ji-fang, Li, Jian, Lu, Ming et al. · 2020 · Cancer Immunology Research
100. Mechanisms regulating T-cell infiltration and activity in solid tumors
     Lanitis, E., Dangaj, D., Irving, M., Coukos, G. · 2017 · Annals of Oncology